Navigation Links
FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research
Date:4/18/2008

BALTIMORE, April 18 /PRNewswire/ -- FASgen, Inc. presented at the AACR meeting in San Diego efficacy and toxicology data on FAS31, FASgen's lead compound for ovarian cancer. FAS31 is an inhibitor of fatty acid synthase (FASi), an enzyme that is highly expressed in many human cancers. Numerous studies have shown that pharmacological FAS inhibition is cytotoxic to a variety of human xenograft models without toxicity. In preliminary toxicity studies, FAS31 showed no observable toxicity in normal tissues in the rat or mouse.

FAS31 inhibits fatty acid synthesis in SKOV3 human ovarian cancer cells in vitro (IC-50 = 6.09 +/- 0.4 ug/ml) at a concentration similar to induce cytotoxicity (LC-50 = 5.2 +/- 2.0 ug/ml). FAS 31 (50 mg/kg/day) for 2 weeks substantially inhibited SKOV3 xenograft growth by >90% compared to vehicle. FAS activity in the treated tumor xenografts was reduced by 82%. This is consistent with published in vitro studies where inhibition of FAS pathway activity by at least 20% led to brisk apoptosis in human cancer cells. No gross or microscopic organ toxicity was identified.

In maximally tolerated dose studies, male and female rats were challenged with increasing single doses of FAS 31 ranging from 0 (vehicle) to 1000 mg/Kg ip or po and followed for 8 days. Aside from one death in the female rats treated with 1000 mg/Kg (ip), no overt toxicity was noted in any other animals; normal motor activity was recorded. In a five-day rat toxicology study, male and female rats were challenged with twice-daily doses of FAS 31 from 0 to 500 mg/Kg ip or orally. No abnormal behavior or distress was noted attributable to FAS 31. All chemistry and hematology studies were within normal limits.

The multiple successful mouse efficacy trials in human ovarian cancer cell lines, showing 80% reduction in SKOV-3 tumor xenografts, and the combination of toxicity, maximum tolerated dose, bioavailability and pK studies lead to the conclusions that FAS31 is efficacious against ovarian cancer tumors, is non-toxic and is a viable pharmacological candidate for anti-cancer therapy.

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

The Company have has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer and the lead compound, FAS31, has demonstrated remarkable efficacy in the reduction in size of tumors in eight different xenograft models, and is in final preparation for starting clinical trials. Additional compounds have the potential of specific therapeutics for obesity and related metabolic disorder. A final group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that

affect one third of the world's population. For more information, visit FASgen's website at http://www.fasgen.com


'/>"/>
SOURCE FASgen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Presents Data on Varespladib at ATVB Meeting
2. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
3. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
4. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
5. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. SGX Presents Preclinical MET Data at AACR
8. ARIUS presents new findings for anti-cancer antibody programs at AACR
9. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
10. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
11. Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... Lithuania, announced today that they have entered into a multiyear collaboration to identify ... CRISPR researchers with additional tools for gene editing across all applications. , Under ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):